About This Fund
Columbus Life Sciences Fund III (FCR) is a EUR 120 million Spanish venture capital fund managed by Columbus Venture Partners SGEIC, S.A., registered with the Spanish CNMV under registration number 326 in April 2021. The fund represents the third flagship vehicle in Columbus Venture Partners' life sciences fund series, raising nearly double the target capitalization of its predecessor Columbus Life Science Fund II (EUR 70 million, 2019), and reflecting growing institutional demand for specialist biotech and pharmaceutical venture exposure in Spain and broader Europe. The fund invests at seed and early stages in life sciences companies with strong scientific foundations and the potential to advance transformative therapeutic or industrial biotech products.
Columbus Life Sciences Fund III applies the firm's distinctive model of combining targeted seed-stage capital with infrastructure creation, actively working alongside portfolio companies to build the operational, regulatory, and commercial capabilities needed to progress through development stages. Columbus Venture Partners has developed deep expertise across drug development, gene therapy, biologics, and biotech-enabled industrial applications, and invests primarily in companies based in Spain's growing biotech ecosystem with the ability to access international capital markets and clinical networks. The fund's investment period ran from 2021 to 2023, during which it built a portfolio of ten companies reflecting the firm's focus on early-stage innovations with high scientific differentiation.
Columbus Life Sciences Fund III has been succeeded by Columbus Life Sciences Fund IV (2023, EUR 150 million), continuing the fund family's trajectory of increasing scale and institutional confidence. Columbus Venture Partners has generated a strong cumulative exit track record across its fund family, with notable realizations including AskBio, Aura Biosciences, Algenex, Viralgen, Sanifit Therapeutics, and the 2026 sale of Syngoi Technologies to Artis BioSolutions. The manager operates from the Valencia Technology Park in Paterna and has established itself as one of Spain's most active and recognized dedicated life sciences venture capital managers with over a decade of consistent activity in the sector.